A newly registered trial, PATCH, will evaluate whether psilocybin can increase the effectiveness of amblyopia therapy in adults with amblyopia. The study will assess whether ingesting psilocybin, a naturally occurring psychoactive compound, can enhance treatment outcomes in this population.
NYU Langone Health has registered a double-blind, parallel-design, placebo-controlled, two-centre randomised controlled trial of single-dose psilocybin-assisted psychotherapy in 100 outpatients with early-stage breast cancer. The trial is designed to evaluate efficacy and psychological mechanisms for fear of cancer recurrence (FCR), anxiety and depression distress and quality of life, comparing a single 25mg oral dose of psilocybin with a single 5mg oral dose as an active placebo, both delivered with a psychotherapy platform.
Why it matters: The registry record sets out a two-centre design with an active placebo, so readers can see how the trial plans to separate psilocybin from expectancy in fear of cancer recurrence.
A newly registered open-label trial will use PET imaging to study cerebral metabolism in healthy adults after a single dose of ayahuasca. The registry entry lists no sample size, dosing details or results.
A double-blind, randomised, placebo-controlled trial registered on ClinicalTrials.gov assigned 28 healthy volunteers to four single-dose groups of seven: ayahuasca 0.5 mL/kg, 1.0 mL/kg, 1.5 mL/kg or placebo. The study examined effects on personality. No results are reported in the registration entry.